|
|
News for Healthier Living
New Therapeutic Target Expands Options for Multiple Myeloma
In a Phase I clinical trial, the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma.
July 22, 2026
July 24 2026July 23 2026July 22 2026July 21 2026July 20 2026July 17 2026July 16 2026July 15 2026July 14 2026July 13 2026July 12 2026
|
|
|
|
|